

Press Release

Governor Washington State (USA) visits Jubilant Life Sciences headquarters in Noida

Noida (UP), India, October 05, 2012

Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company announced today that Ms. Christine Gregoire, Governor, Washington State (USA), visited the Company headquarters at Noida. The Company has a key relationship with the state of Washington (USA), its US FDA approved manufacturing facility for sterile injectables and allergy therapy products is based in Spokane (Washington).

Commenting on the visit, the Governor Christine Gregoire, said *"We come here to India as the first delegation ever to visit from the state of Washington. We have already developed a wonderful partnership and we are so proud to be the home of Jubilant in Spokane, Washington. By investing in our community and technical colleges, as well as our research universities, we can provide the skilled workforce that Jubilant needs to prosper, resulting in more family-wage jobs in our community".*

Commenting on the development, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, said, *"It's important for Jubilant, being an integrated pharmaceutical player to have strong presence in USA, the largest global pharmaceuticals market. Around 50% of our assets are in North America with investments of close to \$ 300Mn in USA, providing job opportunities to about 1000 people. Currently we have two US FDA approved facilities, one for sterile injectables in Spokane, Washington and one for oral dosage formulations in Salisbury, Maryland, besides clinical research business in New Jersey. We enjoy globally recognised leadership positions as quality manufacturer and innovative solutions provider. We have a strong platform to consolidate this position for further growth thereby providing value creation opportunities for all stakeholders".*

In Spokane, Jubilant Life Sciences operates through its subsidiary, Jubilant HollisterStier Laboratories, LLC. It has 610 employees working in this facility. The Company has leadership position in the contract manufacturing of sterile injectables and allergenic extracts business in the US.

"Our operations in Spokane serve as a critical basis for our manufacturing and R&D operations in sterile injectables and allergy products. We look forward to working with the State and local officials in supporting our growth plans", said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of ~6300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 90 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com



For more information please contact:

For Media

Sudhakar Safaya
Jubilant Life Sciences Limited
+91 - 0120 4361034 ; +91 - 9811219334
Email - sudhakar_safaya@jubl.com

For Investors

Nidhi Aggarwal
Jubilant Life Sciences Limited
Ph: +91-120 4361002
E-mail: nidhi_aggarwal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 -22 6645 1209
E-mail: siddharth@cdr-india.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.